Early QT assessment - how can our confidence in the data be improved?

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 642-648

  Darpo, Borje ^a   Garnett, Christine ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b CERTARA   (United States)

Author keywords

Early QT assessment; Healthy volunteers; PK PD thorough QT study; QT; QT QTc

Indexed keywords

MOXIFLOXACIN;

ARTICLE; CARDIOVASCULAR PARAMETERS; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; EARLY QT ASSESSMENT; ELECTROCARDIOGRAM; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; THOROUGH QT; TREATMENT RESPONSE;

EARLY QT ASSESSMENT; HEALTHY VOLUNTEERS; PK/PD THOROUGH QT STUDY; QT; QT/QTC;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME;

EID: 84886930929     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12068     Document Type: Article

References (28)

1. ICH Harmonized Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005. Available at: http://www.ich.org/cache/compo/276-254-1.html (last accessed 21 December 2012).
2. Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 2005; 28: 115-125.
3. Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK. Electrocardiographic assessment for therapeutic proteins - scientific discussion. Am Heart J 2010; 160: 627-634.
4. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 2009; 157: 827-836. 836.
5. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 2009; 159: 49-57.
6. Yan LK, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat 2010; 20: 497-507.
7. Zhang J. Testing for positive control activity in a thorough QTc study. J Biopharm Stat 2008; 18: 517-528.
8. Bouvy JC, Koopmanschap MA, Shah RR, Schellekens H. The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther 2012; 91: 281-288.
9. Allen MJ, Nichols DJ, Oliver SD. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 2000; 50: 247-253.
10. Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. Br J Clin Pharmacol 1981; 11: 187-195.
11. Phillips L, Grasela TH, Agnew JR, Ludwig EA, Thompson GA. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clin Pharmacol Ther 2001; 70: 370-383.
12. Piergies AA, Ruo TI, Jansyn EM, Belknap SM, Atkinson AJ Jr. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clin Pharmacol Ther 1987; 42: 107-112.
13. Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn 2001; 28: 555-575.
14. Whiting B, Holford NH, Sheiner LB. Quantitative analysis of the disopyramide concentration-effect relationship. Br J Clin Pharmacol 1980; 9: 67-75.
15. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005; 7: E609-E624.
16. Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration - QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 2011; 51: 1152-1162.
17. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornoe CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008; 48: 13-18.
18. Han DW, Park K, Jang SB, Kern SE. Modeling the effect of sevoflurane on corrected QT prolongation: a pharmacodynamic analysis. Anesthesiology 2010; 113: 806-811.
19. van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Br J Clin Pharmacol 2012; 73: 402-410.
20. Darpo B, Fossa AA, Couderc JP, Zhou M, Schreyer A, Ticktin M, Zapesochny A. Improving the precision of QT measurements. Cardiol J 2011; 18: 401-410.
21. Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV. Creation of a knowledge management system for QT analyses. J Clin Pharmacol 2011; 51: 1035-1042.
22. Stockbridge N, Zhang J, Garnett C, Malik M. Practice and challenges of thorough QT studies. J Electrocardiol 2012; 45: 582-587.
23. Tsong Y, Yan LK, Zhong J, Nie L, Zhang J. Multiple comparisons of repeatedly measured response: issues of validation testing in thorough QT/QTc clinical trials. J Biopharm Stat 2010; 20: 654-664.
24. Ferber G. Data-based simulations to assess the power for detecting moxifloxacin-like QTc responses using concentration- QTc - models in small phase-1 studies. Presentation at the CSRC Think Tank meeting, February 2012.
25. ICH Harmonized Tripartite Guideline E14. ICH E14 Question and Answers, 2012. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R1_step4.pdf (last accessed 21 December 2012).
26. Malik M, Zhang J, Johannesen L, Hnatkova K, Garnett C. Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability. Heart Rhythm 2011; 8: 1777-1785.
27. Garnett CE. Value of evaluation concentration: QTc relationship in regulatory decision making. Presentation at ASCPT 2012 Annual meeting Workshop: Evaluation of concentration: QTc relationship in early clinical development: is a thorough QT study necessary? 2012.
28. International Consortium for Innovation and Quality in Pharmaceutical Development. Available at: http://www.iqconsortium.com/ (last accessed 21 December 2012).